The effect of subconjunctival suramin on corneal neovascularization in rabbits

Cornea

Volumn 29, Issue 1, 2010, Pages 86-92

  Lee, Hyun Soo ^a,b   Chung, Sung Kun ^b  

^a Laboratory of Visual Science   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Bevacizumab; Cornea; Neovascularization; Suramin; VEGF

Indexed keywords

BALANCED SALT SOLUTION; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; SURAMIN; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; FIBROBLAST GROWTH FACTOR 2; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; CORNEA STROMA; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL RABBIT; MALE; NONHUMAN; PRIORITY JOURNAL; SUTURE; ANIMAL; COMPARATIVE STUDY; CONJUNCTIVA; DISEASE MODEL; INJECTION; METABOLISM; RABBIT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CONJUNCTIVA; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLAST GROWTH FACTOR 2; INJECTIONS; MALE; RABBITS; SURAMIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 75649091195     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e3181ae91e3     Document Type: Article

References (32)

1. Stromblad S, Cheresh DA. Integrins, angiogenesis and vascular cell survival. Chem Biol. 1996;3:881-885.
2. Chang JH, Gabison EE, Kato T, et al. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12:242-249.
3. Cockerill GW, Gamble JR, Vadas MA. Angiogenesis: models and modulators. Int Rev Cytol. 1995;159:113-160.
4. Pandya NM, Dhalla NS, Santani DD. Angiogenesis: a new target for future therapy. Vascul Pharmacol. 2006;44:265-274.
5. Chang JH, Azar DT, Hernandez-Quintela E, et al. Characterization of angiostatin in the mouse cornea. Invest Ophthalmol Vis Sci. 2000;41: S832.
6. Folkman J. Antiangiogenesis in cancer therapy: endostatin and its mechanisms of action. Exp Cell Res. 2006;312:594-607.
7. Yoeruek E, Ziemssen F, Henke-Fahle S, et al. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol. 2008; 86:322-328.
8. Bocci G, Danesi R, Benelli U, et al. Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo. Cancer Chemother Pharmacol. 1999;43:205-212.
9. Hurwitz H, Fehrenbacher L, Novotny W. Bevacizumab plusirinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
10. Avery RL, Pieramici DJ, Rabena MD. Intravitreal bevacizumab(Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006; 113:363-372.
11. Spaide RF, Fisher YL. Intravitreal Bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006;26:275-278.
12. Papathanassiou M, Theodossiadis PG, Liarakos VS, et al. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol. 2008;145:424-431.
13. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114:855-859.
14. Hawking, F. Suramin with special reference to onchocerciasis. Adv Pharmocol Chemother. 1989;15:289-290.
15. Meyers MO, Gagliardi AR, Flattmann GJ, et al. Suramin analogs inhibit human angiogenesis in vitro. J Surg Res. 2000;91:130-134.
16. Marchetti D, Reiland J, Erwin B, et al. Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues. Int J Cancer. 2003;104:167-174.
17. Gagliardi AR, Kassack M, Kreimeyer A, et al. Antiangiogenic and antiproliferative activity of suramin analogues. Cancer Chemother Pharmacol. 1998;41:117-124.
18. Waltenberger J, Mayr U, Frank H, et al. Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action. J Mol Cell Cardiol. 1996;28:1523-1529.
19. Joussen AM, Kruse FE, Rohrschneider K, et al. Inhibition of ocular neovascularization by suramin. Vision Res. 1995;35:94-95.
20. Ord JJ, Streeter E, Jones A, et al. Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma. Br J Cancer. 2005;92:2140-2147.
21. Schmidt-Erfurth U, Hasan T, Schomacker K. In vivo uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularization. Lasers Surg Med. 1995;17:178-188.
22. Lee DH, ChoHJ, Kim JT, et al. Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia. Cornea. 2001;20:738-742.
23. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 2000;41:2514-2522.
24. Azar DT. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2006;104:264-302.
25. Penn JS, Madan A, Caldwell RB, et al. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 2008;27:331-371.
26. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol. 2001;61:253-270.
27. Cao Y. Molecular mechanisms and therapeutic development of angiogenesis inhibitors. Adv Cancer Res. 2008;100:113-131.
28. Bock F, Onderka J, Dietrich T, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci. 2007;48:2545-2552.
29. Mietz H, Chevez-Barrios P, Feldman RM, et al. Suramin inhibits wound healing following filtering procedures for glaucoma. Br J Ophthalmol. 1998;82:816-820.
30. Yoeruek E, Spitzer MS, Tatar O, et al. Safety profile of bevacizumab on cultured human corneal cells. Cornea. 2007;26:977-982.
31. Kaur M, Reed E, Sartor O, et al. Suramin's development: what did we learn? Invest New Drugs. 2002;20:209-219.
32. Kim TI, Kim SW, Kim S, et al. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Cornea. 2008;27:349-352.